Table 1

Demographics of the conventional and drug-eluting balloon groups

DemographicsDEB groupConventional groupP value
Number2936N/A
Female sex01 (2.8%)0.366
Age (mean)64.7±9.4 (47–88)63.6±7.6 (48–78)0.632
NIHSS score before PTAS6±2 (2–10)7±2 (0–12)0.356
NIHSS score 7 days after PTAS4±2 (1–8)3±1 (0–6)0.111
mRS score before PTAS1±1 (0–2)1±1 (0–2)0.351
mRS score 7 days after PTAS1±1 (0–2)1±1 (0–2)0.351
Etiology for radiation therapy
(nasopharyngeal or oropharyngeal cancer/larynx or hypopharyngeal cancer)
24/5
(82.8%/17.2%)
27/9
(75.0%/25.0%)
0.449
Stenotic location
(ICA only/CCA only/ICA+CCA)
20/6/3
(69.0%/20.7%/10.3%)
23/9/4
(63.9%/25.0%/11.1%)
0.905
Treated lesion laterality
(right/left)
16/1319/170.847
Presence of neurological symptoms* before PTAS20 (69.0%)18 (50.0%)0.123
Risk factors
 Hypertension20 (69.0%)26 (72.2%)0.774
 Diabetes mellitus10 (34.5%)10 (27.8%)0.560
 Smoking23 (79.3%)26 (72.2%)0.510
 Hyperlipidemia15 (51.7%)21 (58.3%)0.594
Preprocedural DSA
 DSA stenosis (%)79.28±10.56 (60.9–94.5)78.85±7.32 (65.2–94.3)0.845
 Lesion length (cm)2.77±1.74 (0.86–7.73)2.40±0.95 (1.03–5.41)0.286
 DEB diameter (mm)4.93±1.20 (3.5–7)N/AN/A
 DEB length (cm)6.00±1.67 (3–8)N/AN/A
Postprocedural DSA and periprocedural neurological complications
 Residual stenosis on control DSA (%)16.46±3.85 (11.6–24.1)17.69±4.36 (10.4–28.4)0.237
  • The degrees of stenosis were calculated based on the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method.20

  • Results are shown as number (%) or mean±SD (range).

  • *Neurological symptoms before PTAS were referred to amaurosis, transient ischemic attack, or minor or major stroke.

  • CCA, common carotid artery; DEB, drug-eluting balloon; DSA, digital subtraction angiography; ICA, internal carotid artery; mRS, modified Rankin Scale; NIHSS, National Insitutes of Health Stroke Scale; PTAS, percutaneous angioplasty and stenting.